Effects and clinical implications of sacubitril/valsartan on left ventricular reverse remodeling in patients affected by chronic heart failure: A 24-month follow-up

•Congestive heart failure is a major cause of morbidity and mortality worldwide.•Sacubitril/valsartan improved left ventricular remodeling and ejection fraction in a real-world setting, mostly within 12 months.•Female gender and primitive cardiomyopathy were predictors of favorable remodeling.•Sacubitril/valsartan should be initiated early to maximize its beneficial effects.